Palliative Care

November 8, 2021

THC:CBD Being conducted 1:1 2.5:2.5 / 10:10 / 30:30

Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. This study aims to define the role of a 1:1 delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD) cannabinoid preparation in the management of symptom burden in patients with advanced cancer undergoing standard palliative care.
    Your Cart
    Your cart is emptyReturn to Shop